analyzeportfolio
Nasdaq · Healthcare

Pennant Group, Inc. (PNTG)

As-reported financials and SEC filings for Pennant Group, Inc. The latest annual period is FY2025. The latest reported quarter is Q2 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.

About Pennant Group, Inc.

Pennant Group, Inc. provides healthcare services including home health, hospice, and senior living across multiple states in the U.S. It operates 172 home health and hospice agencies and 63 senior living communities offering assisted living, independent living, and memory care. The company serves patients, residents, and clients of all ages, with a focus on the senior population, and works with payors such as Medicare, Medicaid, private pay patients, and managed care organizations.

Snapshot

Revenue
$947.7M
Revenue growth (YoY)
36.3%
Net income
$29.6M
Diluted EPS
$0.84
Gross margin
Operating margin
5.5%
Net margin
3.1%
FCF margin
3.8%
ROE
7.9%
net income / fiscal-year-end equity
P/E
40.7×
trailing when available, otherwise FY EPS
Market cap
$1.30B
Long-term debt / equity
0.45×
non-current term debt only

Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.

What changed at Pennant Group

  • Revenue grew 36.3% to $948M in FY2025, faster than the 27.6% the year before.
  • Operating margin is 5.5% in FY2025, +4.4 pp against 1.1% in FY2021.
  • Most recent quarter Q2 FY2026: revenue $298M, up 35.8% from Q2 FY2025.
  • Free cash flow was $36M in FY2025, 3.8% of revenue.
  • Net income rose 31.1% to $30M in FY2025.

Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.

Peer comparison

Where Pennant Group’s fundamentals sit among the 558 Healthcare companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).

Operating margin5.5%
59th percentile of 399
Net margin3.1%
60th percentile of 418
FCF margin3.8%
52nd percentile of 372
Revenue growth (YoY)+36.3%
79th percentile of 538
ROE7.9%
70th percentile of 473
P/E40.7×
78th percentile of 201
Long-term debt / equity0.45×
46th percentile of 243
Short interest2.41d
25th percentile of 557

No reported insider purchases (code P) in the last 90 days; 5 insider sales totaling $531,946. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →

Percentiles describe where a figure sits among sector peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.

Institutional ownership

Held by 1 of the superinvestors we track (plus 6 quant / multi-strat books), based on each investor’s most recent 13F; periods vary by investor (newest: Q2 2026).

Conviction investors
1
+6 quant / multi-strat
Initiated / added
3
0 new, 3 added
Reduced / exited
4
4 trimmed, 0 exited
Combined position
$39.0M
reported long value
InvestorAs ofPosition valueSharesChange
First Eagle Investment ManagementQ2 2026$21.1M570.5KAdded
Millennium ManagementquantQ2 2026$4.6M124.7KReduced
D. E. ShawquantQ2 2026$4.6M124.6KReduced
Two Sigma InvestmentsquantQ2 2026$2.9M78.4KReduced
Citadel AdvisorsquantQ2 2026$2.7M73.0KAdded
Renaissance TechnologiesquantQ2 2026$1.8M48.2KReduced
AQR Capital ManagementquantQ2 2026$1.3M35.5KAdded

From quarterly Form 13F filings, which can be up to 45 days delayed. Long US-listed positions only: excludes short positions, options, cash, bonds, and non-US holdings, so this is not a manager’s complete portfolio. Counts are of the investors we track, not all institutions. Not investment advice.

Recent insider activity

Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.

Buys (90d)
0
code P
Bought (90d)
code P value
Sells (90d)
5
$532K
Reported activity
Net selling
by $ value, 90d
Trade dateInsiderTypeSharesPriceValue
2026-08-06
filed 2026-08-10
Guerisoli BrentChief Executive OfficerSell4.3K$38.52$165K
2026-08-06
filed 2026-08-10
Steik Jason PaulChief Clinical OfficerSell1.4K$38.52$54K
2026-08-06
filed 2026-08-10
Cheney Kirk SterlingEVP, GC and Corp SecySell1.4K$38.52$54K
2026-07-10
filed 2026-07-14
Guerisoli BrentChief Executive OfficerSell3.2K$41.56$131K
2026-07-07
filed 2026-07-09
Guerisoli BrentChief Executive OfficerSell3.2K$40.51$128K
2026-05-22
filed 2026-05-27
Guerisoli BrentChief Executive OfficerSell2.3K$35.08$79K
2026-05-22
filed 2026-05-27
Guerisoli BrentChief Executive OfficerSell2.0K$35.08$71K
2026-05-22
filed 2026-05-27
Guerisoli BrentChief Executive OfficerSell200$35.10$7K
2026-05-22
filed 2026-05-27
Guerisoli BrentChief Executive OfficerSell22$34.86$767

Reported non-derivative purchases and sales (codes P/S) — which may be open-market or private; excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.

Short interest

Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.

Shares short
769.9K
settled 2026-08-14
Change vs prior
+15.4%
vs previous settlement
Days to cover
2.41
at avg daily volume
Avg daily volume
319.8K
FINRA reported
SettlementShares shortChangeDays to cover
2026-08-14769.9K+15.4%2.41
2026-07-31667.3K-8.0%2.93
2026-07-15724.9K-7.1%2.03
2026-06-30780.2K+23.6%2.17
2026-06-15631.0K+5.1%2.35
2026-05-29600.3K-5.5%3.21
2026-05-15635.3K-2.2%1.92
2026-04-30649.6K+0.9%3.30

Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.

Income statement (as reported)

 FY2025FY2024FY2023FY2022FY2021
Revenue$947.7M$695.2M$544.9M$473.2M$439.7M
Gross profit
Operating income$51.9M$38.1M$25.2M$12.7M$4.7M
Net income$29.6M$22.6M$13.4M$6.6M$2.7M
Diluted EPS$0.84$0.70$0.44$0.22$0.09

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Balance sheet (as reported)

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Cash flow (as reported)

 FY2025FY2024FY2023FY2022FY2021
Operating cash flow$48.3M$39.3M$33.1M$9.0M$-18.2M
Capital expenditure$12.0M$9.0M$8.1M$14.2M$6.3M
Free cash flow$36.3M$30.3M$25.0M$-5.1M$-24.5M

Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (hover to see the figure as filed). Full details: where the numbers come from.

Quarterly trend (as reported)

QuarterRevenueRevenue YoYNet incomeDiluted EPS
Q2 FY2026$298.0M35.8%$9.1M$0.25
Q1 FY2026$285.4M36.0%$8.5M$0.24
Q4 FY2025$289.3M53.2%$8.6M$0.24
Q3 FY2025$229.0M26.8%$6.1M$0.17
Q2 FY2025$219.5M30.1%$7.1M$0.20
Q1 FY2025$209.8M33.7%$7.8M$0.22
Q4 FY2024$188.9M29.4%$5.8M$0.16
Q3 FY2024$180.7M28.9%$6.2M$0.20

Latest 8 reported quarters, from company XBRL filings on SEC EDGAR.

Company facts

ExchangeNasdaq
SectorHealthcare
SIC industryServices-Health Services
Latest annual periodFY2025 (ended December 31, 2025)
Latest reported quarterQ2 FY2026 (ended June 30, 2026)
Oldest indexed filing2019
SEC CIK1766400

Selected SEC filings

10-K2026-02-26
View on EDGAR →
10-Q2026-08-05
View on EDGAR →
10-Q2026-05-06
View on EDGAR →
10-Q2025-11-05
View on EDGAR →
8-K2026-08-05
View on EDGAR →
8-K2026-05-20
View on EDGAR →
8-K2026-05-06
View on EDGAR →
8-K2026-02-25
View on EDGAR →

Largest Healthcare peers

All Healthcare companies →

Monitor PNTG

Get an alert when Pennant Group files something material, see which superinvestors own it, and ask its filings a question with cited answers.

Monitor PNTG free

Includes one free filing-grounded research answer. Or check your whole portfolio, no account needed.

Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.